Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD) Study of Continuous Subcutaneous Insulin Infusion (CSII) in Participants With Type 1 Diabetes Mellitus (T1DM)

NCT01275131 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Insulin aspart
DRUG: Recombinant human hyaluronidase PH20 (rHuPH20)

Sponsor

Halozyme Therapeutics